235 related articles for article (PubMed ID: 34584238)
1. Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.
Liang EC; Chen C; Lu R; Mannis GN; Muffly L
Bone Marrow Transplant; 2021 Dec; 56(12):3091-3093. PubMed ID: 34584238
[TBL] [Abstract][Full Text] [Related]
2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of
Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM
J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M
Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553
[TBL] [Abstract][Full Text] [Related]
7. Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.
Helbig G; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kopińska A; Boral K; Grygoruk-Wiśniowska I; Stachowicz M; Karolczyk A
Ann Hematol; 2020 Aug; 99(8):1845-1853. PubMed ID: 32333156
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
9. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB
Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660
[TBL] [Abstract][Full Text] [Related]
10. Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.
Wan L; Ding S; Xu M; Lv K; Du Y; Wu D; Xu M; Liu Y
Int J Hematol; 2022 Nov; 116(5):731-743. PubMed ID: 35857193
[TBL] [Abstract][Full Text] [Related]
11. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
[TBL] [Abstract][Full Text] [Related]
12. Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.
Grunwald MR; Tseng LH; Lin MT; Pratz KW; Eshleman JR; Levis MJ; Gocke CD
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1989-95. PubMed ID: 25240816
[TBL] [Abstract][Full Text] [Related]
13. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
14. [Hematopoietic cell transplantation for FLT3-mutated acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2022; 63(9):1242-1251. PubMed ID: 36198550
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy for
Burchert A
Haematologica; 2021 Mar; 106(3):664-670. PubMed ID: 33472354
[TBL] [Abstract][Full Text] [Related]
17. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
18.
Lee JM; Park S; Hwang I; Kang D; Cho BS; Kim HJ; Ahn A; Kim M; Kim Y
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551616
[TBL] [Abstract][Full Text] [Related]
19. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]